Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 12-Month High on Analyst Upgrade

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) reached a new 52-week high during mid-day trading on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $265.00 to $276.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Jazz Pharmaceuticals traded as high as $261.78 and last traded at $260.62, with a volume of 1309913 shares. The stock had previously closed at $251.58.

Other equities research analysts have also recently issued research reports about the company. Wells Fargo & Company increased their price objective on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday. Leerink Partners boosted their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $287.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday. Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, June 29th. Finally, UBS Group reissued a “buy” rating and set a $315.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $272.74.

Insider Buying and Selling

In other news, Director Rick E. Winningham sold 2,741 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.57, for a total transaction of $662,143.37. Following the sale, the director owned 9,567 shares in the company, valued at approximately $2,311,100.19. The trade was a 22.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president owned 51,549 shares in the company, valued at approximately $11,950,604.67. This trade represents a 2.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 13,098 shares of company stock valued at $3,131,906 over the last 90 days. 4.10% of the stock is currently owned by company insiders.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Raised outlook and strong revenue growth: Jazz reported second-quarter revenue of approximately $1.21 billion, up 15.5% year over year and above the $1.11 billion analyst estimate. The company raised its 2026 revenue forecast to approximately $4.60 billion-$4.75 billion, ahead of consensus expectations near $4.5 billion. Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Core products continued to perform: Xywav revenue increased 13% year over year, with 525 net patient additions during the quarter, while Epidiolex revenue grew 16%. Management also said it is prepared to launch Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma following FDA approval. Jazz Pharmaceuticals Reports Bullish Q2
• Positive Sentiment: Analyst support increased: Morgan Stanley and Robert W. Baird raised their price targets to $280, with “overweight” and “outperform” ratings, respectively. Needham lifted its target to $292 and maintained a “buy” rating. These revisions reflect improved confidence in Jazz’s growth outlook. Needham Raises Jazz Price Target
• Neutral Sentiment: Upcoming regulatory catalyst: Investors are awaiting the FDA’s August 25 decision date for zanidatamab, which could provide a significant new commercial opportunity if approved. Jazz Prepares for Zanidatamab FDA Decision
• Negative Sentiment: Quarterly earnings missed expectations: Adjusted EPS was $5.71, below consensus estimates ranging from $6.04 to $6.18, although it improved substantially from a loss of $8.25 per share a year earlier. Jazz Q2 Earnings Lag Estimates
• Negative Sentiment: Zepzelca withdrawal: Jazz plans to withdraw Zepzelca from the FDA’s second-line small-cell lung cancer indication, removing an established indication and potentially limiting the drug’s future revenue contribution. Jazz to Withdraw Zepzelca Indication

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP bought a new position in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $127,344,000. Franklin Resources Inc. boosted its holdings in Jazz Pharmaceuticals by 164.0% in the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after acquiring an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Jazz Pharmaceuticals by 160.2% in the fourth quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock worth $197,516,000 after acquiring an additional 715,361 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Jazz Pharmaceuticals by 258.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock worth $93,160,000 after acquiring an additional 395,000 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 592.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after acquiring an additional 373,383 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

The firm has a fifty day moving average price of $239.50 and a two-hundred day moving average price of $207.30. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The stock has a market capitalization of $16.28 billion, a P/E ratio of -12,986.56, a P/E/G ratio of 0.22 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period last year, the company posted ($8.25) earnings per share. On average, analysts expect that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.